Loading
A phase 3 trial of GM1 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer is a phase 3 interventional study registered as NCT06994507 by Qilu Pharmaceutical Co., Ltd., with 352 participants planned, started 2025-08-01 and due to reach its primary completion in 2026-09. Interventions recorded: GM1 and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/